Catheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at Scripps’ Structural Heart Intervention and Imaging 2026 Conference

Rhea-AI Summary

Catheter Precision (NYSE American: VTAK) announced that its LockeT suture retention device will be featured in live procedural cases at the Structural Heart Intervention and Imaging: A Practical Approach 2026 conference.

The event runs February 11–13, 2026 at the Hyatt Regency La Jolla at Aventine in San Diego, and inclusion in live cases highlights LockeT's role in workflow efficiency and patient recovery after venous catheter access, according to the company.

Key Figures

Conference dates: February 11–13, 2026

1 metrics

Conference dates February 11–13, 2026 Scripps Structural Heart Intervention and Imaging course

Market Reality Check

Price: $1.87 Vol: Volume 19,499 is below th...

normal vol

$1.87 Last Close

Volume Volume 19,499 is below the 20-day average of 23,238 (about 0.84x average). normal

Technical Price at 1.87 is trading below the 200-day MA of 3.30, reflecting prior weakness.

Peers on Argus

Peers show mixed moves, from -22.76% (NUWE) to +3.70% (VERO), while VTAK was up ...

Peers show mixed moves, from -22.76% (NUWE) to +3.70% (VERO), while VTAK was up 1.63%, suggesting a stock-specific reaction rather than a sector-wide move.

Historical Context

5 past events · Latest: Feb 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 04	LockeT adoption update	Positive	+1.6%	Reported new hospital evaluations, approvals, and strongest January revenue for LockeT.
Jan 22	German market entry	Positive	+10.4%	First LockeT purchase order in Germany, entering a large EP devices market.
Jan 20	VIVO expansion	Positive	-1.9%	VIVO purchase order in Slovenia expanding commercial footprint to 15 countries.
Dec 18	Irish LockeT contract	Positive	+0.9%	First LockeT purchase order and multi‑year commitment at major Irish EP center.
Dec 03	Hungary VIVO tender	Positive	+13.3%	Multi‑year VIVO tender win in Hungary, extending reach in Central/Eastern Europe.

Pattern Detected

Recent news has focused on international expansion and adoption of LockeT and VIVO, with most positive updates followed by positive price reactions, but at least one instance of divergence.

Recent Company History

Over the past few months, Catheter Precision highlighted commercialization of LockeT and VIVO across Europe and new markets. Key milestones included a first LockeT purchase order in Germany on Jan 22, 2026, expansion of VIVO into Slovenia bringing its footprint to 15 countries, and an Irish multi‑year LockeT commitment announced on Dec 18, 2025. Earlier, a multi‑year VIVO tender win in Hungary signaled Central and Eastern European growth. Today’s conference-focused news continues the theme of clinical adoption and visibility for LockeT.

Market Pulse Summary

This announcement highlights increased clinical visibility for LockeT as it appears in live structur...

Analysis

This announcement highlights increased clinical visibility for LockeT as it appears in live structural heart cases at a major Scripps conference from February 11–13, 2026. It follows recent news of international purchase orders and multi‑year commitments for LockeT and VIVO. Context from SEC filings shows a company with growing but still small revenues and going concern risk, so investors may track how such exposure translates into concrete orders and revenue growth over time.

Key Terms

cardiac electrophysiology, suture retention device, structural heart disease, venous catheter access

4 terms

cardiac electrophysiology medical

"pioneer in medical technology for the cardiac electrophysiology market"

The medical specialty that studies and treats the heart’s electrical system — how electrical signals start and travel to make the heart beat and what causes irregular heart rhythms. It matters to investors because tests, procedures and devices from this field (like diagnostic tools, catheters, implants and drugs) drive clinical demand, regulatory reviews and company revenue; think of it as the “wiring and circuit-breakers” sector for the heart that determines market opportunity for related technologies.

suture retention device medical

"its LockeT suture retention device will be highlighted during live procedural cases"

A suture retention device is a small medical tool used during wound closure to hold stitches in place and spread the force of the stitch over a larger area of skin or tissue, similar to how a button or washer prevents a rope from cutting through fabric. For investors, these devices matter because they can reduce wound complications, shorten surgery or recovery time, and lower follow-up costs—factors that affect hospital adoption, reimbursement, and market demand.

structural heart disease medical

"reviews of structural heart disease interventions and cardiovascular imaging"

Structural heart disease describes physical problems with the heart’s valves, walls, chambers or the large vessels that change how blood flows — like a house with broken doors or plumbing that stops water moving correctly. It matters to investors because diagnosing and treating these conditions typically requires specialized devices, procedures and long regulatory reviews, so clinical results, approvals or new technologies can materially affect manufacturers, hospitals and healthcare spending.

venous catheter access medical

"after venous catheter access"

Venous catheter access is the placement of a thin tube into a vein to deliver medications, fluids, nutrition, or to draw blood, functioning like a plumbing tap for the bloodstream. For investors, it matters because the devices, procedures, and infection risks drive hospitals’ purchasing, procedure volumes, treatment safety and costs, which affect revenue and liability for medical-device makers, service providers and healthcare operators.

AI-generated analysis. Not financial advice.

FORT MILL, S.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that its LockeT suture retention device will be highlighted during live procedural cases at the Structural Heart Intervention and Imaging: A Practical Approach 2026 conference. The event, hosted by Scripps Health, will take place from February 11–13, 2026, at the Hyatt Regency La Jolla at Aventine in San Diego.

The Scripps Structural Heart course is a premier educational forum featuring state-of-the-art, live case-based reviews of structural heart disease interventions and cardiovascular imaging. Leading interventional cardiologists from across the country are presenting at the conference and the inclusion of LockeT in live cases underscores the device's growing role in streamlining workflow efficiency and enhancing patient recovery after venous catheter access.

“We are honored to have LockeT showcased at such a prestigious clinical gathering,” said David Jenkins, CEO of Catheter Precision. “As we enter 2026 with strong momentum and expansion into major medical centers like Scripps in Southern California, these live cases provide a vital platform for physicians to witness firsthand the operational and economic advantages of our suture retention technology.”

About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words.  These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.

The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

CONTACTS:

Investor Relations
973-691-2000
IR@catheterprecision.com

# # #

FAQ

When will Catheter Precision (VTAK) showcase LockeT at Scripps' Structural Heart 2026 conference?

LockeT will be showcased during live cases on February 11–13, 2026. According to Catheter Precision, the device will appear in state-of-the-art, live procedural reviews at the Hyatt Regency La Jolla at Aventine in San Diego.

What is the significance of LockeT being used in live cases at the Scripps Structural Heart conference for VTAK?

Being used in live cases signals clinical interest and real-world application for LockeT. According to Catheter Precision, this exposure helps physicians observe operational and economic advantages in venous catheter access workflows.

Where exactly is the Structural Heart Intervention and Imaging: A Practical Approach 2026 conference being held?

The conference takes place at the Hyatt Regency La Jolla at Aventine in San Diego from February 11–13, 2026. According to Catheter Precision, leading interventional cardiologists will present live case-based reviews there.

How does Catheter Precision describe LockeT's clinical benefits in the announcement about Scripps 2026?

The company describes LockeT as streamlining workflow efficiency and enhancing patient recovery after venous catheter access. According to Catheter Precision, live cases let physicians witness these operational and economic advantages firsthand.

Will Catheter Precision's participation at Scripps signal broader adoption of LockeT for VTAK investors?

Participation suggests growing clinical visibility but is not a sales guarantee. According to Catheter Precision, showcasing LockeT at major centers like Scripps supports momentum and expansion into additional medical centers in 2026.